Main Menu

Where our new drug targets come from

In the Cancer Research UK Cancer Therapeutics Unit, we use a number of approaches to identify new drug targets with novel mechanisms of action, including functional genomics or compound libraries that target protein degradation. In addition we use annotated chemical libraries to discover novel pathways in the context of cancer. Finally, we collaborate with basic scientists within the ICR, CRUK network, and beyond.

Diagram showing CRUK CTU data-driven assessment of opportunity and risks

Image: Diagram showing CRUK CTU data-driven assessment of opportunity and risks

Once a novel compound reaches an appropriate level of maturity, we attempt to partner with Pharma companies (for example Merck or AstraZeneca) or investor organisations (for example Syncona or CRT Pioneer Fund) to secure development into the clinical trial phases.

Quick links to more CRUK Cancer Therapeutics Unit pages